ENDV
ENDONOVO THERAPEUTICS, INC.
- PER (TTM)
- -
- PER (Forward)
- -
- EPS (TTM)
- -
- EPS (Forward)
- -
- PBR
- -0.00
- 시가총액
- 180,755
- 배당수익률
- -
- 베타
- -8.45
- 1개월 수익률
- 0.00%
- 3개월 수익률
- 100.00%
- 6개월 수익률
- 0.00%
- 1년 수익률
- -50.00%
- 2년 수익률
- -
- 5일 평균거래량
- 2188857
- 60일 평균거래량
- 1056072
- 1년 평균거래량
- 5563356
- 5d/60d 거래량 비율
- 2.07×
- 60d/1y 거래량 비율
- 0.19×
- 변동성(60일, 연환산)
- 455.19%
- BB 스퀴즈 스코어
- 1.10
- SMA50 비율
- 1.14
- SMA200 비율
- 0.95
- RSI (14)
- 59
- 20일 수렴도
- 0.27
- 52주 최고
- 0.00
- 52주 최저
- 0.00
- 고점 대비
- -66.67%
- 저점 대비
- 100.00%
펀더멘털 갱신: 2026-05-10T08:47:22+00:00 · 시세 갱신: 2026-05-10T06:30:29+00:00
회사 정보
Endonovo Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and distribution of non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of cardio chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular, and peripheral artery disease (PAD) and ischemic stroke. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.